Answers are grounded in this paper and cite their sources.
Background and objectives: Dexamethasone received worldwide coverage after publishing of the Recovery trial.In view of this, we performed a retrospective observational study on the effect of steroids in coronavirus disease 2019 (COVID-19) infection.Methods: A total of 62 patients of COVID-19 were treated with steroids-steroid group (SG), and 49 patients of COVID-19 were given standard of care treatment (SOC).Primary objectives analyzed: 28-day mortality, number of ventilator days, and number of days on oxygen support.Secondary objectives: Length of Intensive Care Unit (ICU) stay, length of hospital stay, and morbidities.Results: The primary objective of 28-day mortality in COVID-19 Acute Respiratory Disease Syndrome (ARDS) -critical + severe patients -were lower in those in SG (21.6%) than in SOC (33.3%).The median number of ventilator days in SG was 7, and it was 9 in SOC.The mean number of days on oxygen support in ARDS critical + severe patients was 5.5±2.2days for those in SG compared with 8.3±1.0 days for those with SOC (p<0.05).The secondary objective of the number of mean ICU days in ARDS critical + severe for SG vs. SOC patients was 9±6.1 vs. 9.5±5.8,which appeared to trend towards a shorter ICU stay in SG patients. Interpretation and Conclusions:The number of days on oxygen support in SG patients was less than for SOC patients and was statistically significant.The other outcomes showed a lower mortality rate, and lower number of ventilator days, in severe and critical SG patients.Although not statistically significant, this showed a general trend towards the treatment benefit of steroids.
No takes yet. Share an insight, caveat, or question.
Sanker et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: